Halozyme Therapeutics (HALO) Posts Q4 EPS of $0.50
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Revenue Growth %: +37.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.50, which may not compare to the analyst estimate of $0.53. Revenue for the quarter came in at $121.7 million versus the consensus estimate of $120.16 million.
GUIDANCE:
Halozyme Therapeutics sees FY2021 EPS of $1.40-$1.55, which may not compare to the consensus of $1.70. Halozyme Therapeutics sees FY2021 revenue of $375-395 million, versus the consensus of $400.15 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Cabot Corp. (CBT) Tops Q4 EPS by 7c, Beats on Revenue; Offers FY EPS Guidance
- Ryman Hospitality Properties (RHP) Tops Q3 EPS by 15c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
